V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215657 | 20130522 | 1.82 | 92.8 | null | 2020-01-10 | 2020-01-10 | Sorafenib | 02 | Y | SORAFENIB | 101204443 |
| 20215659 | 20130523 | 1.71 | 88.6 | Curative (C) | 2018-06-20 | 2018-06-20 | EOX | 02 | N | TRIAL | 100820050 |
| 20215662 | 20130524 | 1.66 | 66.6 | Palliative (P) | null | 2018-08-29 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100597449 |
| 20215663 | 20130525 | 1.71 | 66.1 | null | 2017-07-24 | 2018-01-28 | Oxaliplatin + Raltitrexed | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100108496 |
| 20215665 | 20130526 | 1.63 | 68.2 | null | 2017-03-19 | 2017-04-08 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101029366 |
| 20215666 | 20130527 | 1.81 | 107.4 | Neo-adjuvant (N) | 2020-05-16 | 2020-06-13 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101142360 |
| 20215667 | 20130528 | 1.6 | null | Palliative (P) | 2019-12-28 | 2020-01-11 | Sorafenib | 02 | N | SORAFENIB | 100946863 |
| 20215668 | 20130529 | 1.62 | 64 | Curative (C) | null | 2017-04-09 | Oxaliplatin + Raltitrexed | null | N | OXALIPLATIN + RALTITREXED | 101640089 |
| 20215671 | 20130530 | null | null | Palliative (P) | 2018-10-10 | 2018-10-10 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 99 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101362840 |
| 20215674 | 20130531 | 1.64 | 62 | null | 2019-06-27 | 2019-07-03 | EOX | N | null | CAPECITABINE + RT | 100697678 |
| 20215675 | 20130532 | 1.63 | 76.7 | Neo-adjuvant (N) | 2015-09-13 | 2016-04-04 | Trial Unspecified | 02 | N | TRIAL | 101546556 |
| 20215680 | 20130533 | 1.6 | 96 | Palliative (P) | 2021-11-02 | 2021-12-02 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100949008 |
| 20215682 | 20130534 | 1.7 | 64 | null | 2019-02-05 | 2019-06-06 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 01 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100306761 |
| 20215685 | 20130535 | 1.81 | 85.3 | Palliative (P) | 2017-10-20 | 2017-10-20 | EOX | 2 | N | CETUXIMAB + IRINOTECAN + MDG | 101508837 |
| 20215686 | 20130536 | 1.78 | 85.3 | Palliative (P) | 2016-12-12 | 2016-12-26 | EOX | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100581575 |
| 20215688 | 20130537 | 1.74 | 88.9 | null | null | 2016-11-20 | Sorafenib | 02 | N | SORAFENIB | 101421662 |
| 20215689 | 20130538 | 1.76 | 100.3 | Palliative (P) | 2019-03-18 | 2019-04-10 | Capecitabine 42days + RT | 02 | null | CAPECITABINE + RT | 100573998 |
| 20215690 | 20130539 | 1.57 | 46.5 | Curative (C) | 2016-12-07 | 2016-12-23 | EOX | 02 | Y | OXALIPLATIN + RALTITREXED | 100583102 |
| 20215691 | 20130540 | 0 | 67.1 | Palliative (P) | 2018-12-02 | 2018-12-23 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 101423484 |
| 20215693 | 20130541 | 1.61 | 96 | null | 2018-10-06 | 2018-11-08 | Trial Unspecified | 99 | null | TRIAL | 100355171 |
| 20215694 | 20130542 | 1.82 | 60 | Curative (C) | 2017-07-25 | 2017-10-07 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101437009 |
| 20215695 | 20130543 | 1.67 | 112 | Neo-adjuvant (N) | 2017-09-13 | 2018-01-08 | Sorafenib | 02 | N | SORAFENIB | 100227345 |
| 20215701 | 20130544 | 1.87 | 48.5 | Disease modification (D) | 2017-10-10 | 2017-11-14 | EOX | 02 | N | EOX | 100479367 |
| 20215704 | 20130545 | 1.55 | 76.3 | Neo-adjuvant (N) | 2019-03-08 | 2019-03-10 | Capecitabine 35days + RT | 02 | Y | CAPECITABINE + RT | 100902126 |
| 20215706 | 20130546 | 1.72 | 101.2 | 03 | 2019-07-07 | 2019-07-22 | Trial Unspecified | 02 | N | TRIAL | 101460505 |
| 20215707 | 20130547 | 1.46 | 72 | Curative (C) | 2018-10-17 | 2018-10-31 | Capecitabine 35days + RT | 02 | N | CAPECITABINE + RT | 101813519 |
| 20215709 | 20130548 | 1.79 | null | null | 2018-03-06 | 2018-04-12 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | Y | OXALIPLATIN + RALTITREXED | 100495429 |
| 20215710 | 20130549 | 1.7 | 63.6 | Palliative (P) | 2017-05-21 | 2017-05-22 | Cetuximab + FOLFIRI cycle1 | 2 | null | CETUXIMAB + IRINOTECAN + MDG | 100807570 |
| 20215714 | 20130550 | 1.72 | 84.6 | Palliative (P) | 2018-03-18 | 2018-07-13 | Capecitabine 42days + RT | 02 | N | CAPECITABINE + RT | 100398081 |
| 20215715 | 20130551 | 1.58 | 96.2 | Palliative (P) | 2019-01-04 | 2019-01-06 | EOX | 02 | null | SORAFENIB | 101268376 |
| 20215716 | 20130552 | 1.67 | 68 | null | 2018-03-27 | 2018-04-03 | Cetuximab + FOLFIRI cycle 2 onwards | Y | null | CETUXIMAB + IRINOTECAN + MDG | 101488633 |
| 20215717 | 20130553 | 1.81 | 87.65 | Palliative (P) | 2016-10-18 | 2017-02-12 | Trial Unspecified | 2 | N | TRIAL | 100128154 |
| 20215718 | 20130554 | 1.7 | 48.3 | Neo-adjuvant (N) | 2019-07-01 | 2019-07-02 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100681488 |
| 20215720 | 20130555 | null | 90.6 | Palliative (P) | 2018-02-02 | 2018-02-13 | Cetuximab + FLUOROURACIL + OXALIPLATIN | N | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100918644 |
| 20215721 | 20130556 | 1.56 | 73.4 | null | 2017-12-06 | 2017-12-15 | EOX | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100662723 |
| 20215725 | 20130557 | 1.57 | 61.8 | null | 2019-02-25 | 2019-03-12 | Capecitabine 5days + RT | N | null | CAPECITABINE + RT | 101322806 |
| 20215726 | 20130558 | 1.65 | 57 | Adjuvant (A) | 2017-11-10 | 2018-03-13 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 101127910 |
| 20215731 | 20130559 | 1.85 | 80.4 | Palliative (P) | 2017-05-16 | 2017-06-04 | Cetuximab + FOLFIRI cycle1 | 1 | null | CETUXIMAB + IRINOTECAN + MDG | 100880529 |
| 20215732 | 20130560 | 1.75 | 85.8 | Curative (C) | 2018-01-23 | 2018-01-27 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101453556 |
| 20215733 | 20130561 | 1.82 | 57.1 | Neo-adjuvant (N) | 2020-05-01 | 2020-05-10 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100738290 |
| 20215734 | 20130562 | 1.74 | 74.2 | Neo-adjuvant (N) | 2016-12-29 | 2017-12-16 | EOX | 02 | N | EOX | 101039427 |
| 20215735 | 20130563 | 1.61 | 71.9 | Palliative (P) | 2018-03-07 | 2018-03-07 | CETUXIMAB + OXALIPLATIN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101765996 |
| 20215736 | 20130564 | 1.72 | 101.7 | Neo-adjuvant (N) | 2020-09-22 | 2020-09-29 | Oxaliplatin + Raltitrexed | 01 | N | OXALIPLATIN + RALTITREXED | 101436256 |
| 20215737 | 20130565 | 1.85 | 93.8 | Palliative (P) | 2020-02-14 | 2020-03-10 | Sorafenib | 02 | N | SORAFENIB | 101860412 |
| 20215738 | 20130566 | 1.79 | 76.2 | null | 2020-06-13 | 2020-06-14 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100982184 |
| 20215740 | 20130567 | 1.76 | 99.7 | Palliative (P) | 2019-07-04 | 2019-07-04 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101858357 |
| 20215741 | 20130568 | 1.76 | 68.1 | null | 2019-03-05 | 2019-03-16 | Panitumumab + Irinotecan + MdG | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101602778 |
| 20215742 | 20130569 | 0 | 60.4 | 03 | 2020-07-14 | 2020-08-21 | Oxaliplatin + Raltitrexed | Y | N | OXALIPLATIN + RALTITREXED | 100508966 |
| 20215745 | 20130570 | 1.74 | 64 | Neo-adjuvant (N) | 2020-02-08 | 2020-02-08 | Sorafenib | 02 | N | SORAFENIB | 101618457 |
| 20215746 | 20130571 | 1.64 | 59.1 | Palliative (P) | 2018-09-23 | 2018-10-07 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101661166 |